James Clemmer on reimbursement strategy
From IEEE Pulse Industry Corner Live Interview with AngioDynamics CEO Jim Clemmer · · IEEE EMBS
“About two months earlier in October, they actually approved our CPT-1 code, which takes effect January 1 of 26, really close to now. That was amazing. I've been doing this over 30 years. I've never heard of a company that actually got their CPT-1 code approved before their 510K was approved. But that showed how effective our teams were.”
On , James Clemmer, Chief Executive Officer, President & Director at ANGIODYNAMICS INC, spoke about reimbursement strategy during IEEE Pulse Industry Corner Live Interview with AngioDynamics CEO Jim Clemmer on IEEE EMBS.
About James Clemmer
In a December 2025 interview with IEEE Pulse, AngioDynamics CEO Jim Clemmer discussed the company's transformation into a science-driven MedTech innovator focused on cancer and cardiovascular disease. Clemmer described the company's strategy of active portfolio management, stating, "It took active portfolio management, which is easy to say, hard to do. So, we divested some assets that actually provided revenue and profit for the company." He also highlighted the company's market performance, saying, "Now five years post launch, we're already taking a number three position in market share, past three of those really big powerful companies." Clemmer emphasized the importance of physician collaboration, clinical evidence, and early reimbursement strategy in bringing breakthrough medical technologies to market. He noted that AngioDynamics obtained a CPT-1 code before receiving 510K clearance, which he described as unusual in his experience. Clemmer also discussed the challenges of market access, stating, "Market access can be really, really challenging and teams need to really think that through and have a really good strategy." He shared his background starting as a sales representative in 1989 and described how the company engaged with physicians to build trust and support for its products.